脂蛋白關聯磷脂酶A2(LpPLA2)檢測試劑盒(酶聯免疫吸附試驗法)
ELISA Kit for Phospholipase A2 Group VII (LpPLA2)
PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated
- 編號SEA867Mu
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應時長3h
- 檢測范圍0.312-20ng/mL
- 靈敏度最小可檢測劑量小于等于0.114ng/mL.
- 樣本類型Serum, plasma and other biological fluids
- 下載 英文說明書 中文說明書
- 規格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 2722 ¥ 3888 ¥ 17496 ¥ 33048 ¥ 272160
- 欲了解實際交易價格和更多情況，請與當地經銷商聯系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
實驗結果圖
-
標準曲線圖
-
通過ISO 9001、ISO 13485質量體系認證
特異性
本試劑盒用于檢測脂蛋白關聯磷脂酶A2(LpPLA2)，經檢測與其它相似物質無明顯交叉反應。
由于受到技術及樣本來源的限制，不可能完成對所有相關或相似物質交叉反應檢測，因此本試劑盒有可能與未經檢測的其它物質有交叉反應。
回收率
分別于定值血清及血漿樣本中加入一定量的脂蛋白關聯磷脂酶A2(LpPLA2)（加標樣品），重復測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 92-102 | 98 |
| EDTA plasma(n=5) | 94-105 | 99 |
| heparin plasma(n=5) | 83-91 | 87 |
精密度
精密度用樣品測定值的變異系數CV表示。CV(%) = SD/mean×100
批內差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復測定8次，分別計算不同濃度樣本的平均值及SD值。
批內差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內加入適量的脂蛋白關聯磷脂酶A2(LpPLA2)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中脂蛋白關聯磷脂酶A2(LpPLA2)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 89-97% | 89-96% | 98-105% | 87-103% |
| EDTA plasma(n=5) | 84-99% | 93-102% | 87-97% | 80-93% |
| heparin plasma(n=5) | 78-97% | 79-101% | 88-96% | 83-92% |
穩定性
經測定，試劑盒在有效期內按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環境條件需盡量保持一致，尤其是實驗室內溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本的準備；
2. 加樣（標準品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100µL，37°C孵育1小時；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數。
實驗原理
將脂蛋白關聯磷脂酶A2(LpPLA2)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標準品或標本，其中的脂蛋白關聯磷脂酶A2(LpPLA2)與連接于固相載體上的抗體結合，然后加入生物素化的脂蛋白關聯磷脂酶A2(LpPLA2)抗體，將未結合的生物素化抗體洗凈后，加入HRP標記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉化成藍色，并在酸的作用下轉化成最終的黃色。顏色的深淺和樣品中的脂蛋白關聯磷脂酶A2(LpPLA2)呈正相關。用酶標儀在450nm波長下測定吸光度(O.D.值)，計算樣品濃度。
增值服務
相關產品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA867Mu03 | 脂蛋白關聯磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA867Mu04 | 脂蛋白關聯磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA867Mu01 | 脂蛋白關聯磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA867Mu02 | 脂蛋白關聯磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA867Mu02 | 脂蛋白關聯磷脂酶A2(LpPLA2)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA867Mu03 | 脂蛋白關聯磷脂酶A2(LpPLA2)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA867Mu01 | 脂蛋白關聯磷脂酶A2(LpPLA2)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA867Mu81 | 脂蛋白關聯磷脂酶A2(LpPLA2)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| LAA867Mu71 | 脂蛋白關聯磷脂酶A2(LpPLA2)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| SEA867Mu | 脂蛋白關聯磷脂酶A2(LpPLA2)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA867Mu | 脂蛋白關聯磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Science & Sports | The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women [ScienceDirect: S0765159710000262] |
| Metabolic Syndrome and Related Disorders | Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease [Wiley: source] |
| 34 | Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study [PubMed: 22240497] |
| PLoS ONE | Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo [PubMed: PMC3759413] |
| China Pharmacy | Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats [Source] |
| Atherosclerosis | Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. [Pubmed: 23958269] |
| Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus [Hindawi: 278063] |
| Health | The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia [Scirp:Source] |
| Biology Bulletin | In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood [Springer:Source] |
| Gynecol Endocrinol. | Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus. [Pubmed:24397392] |
| Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus [Pubmed:24818163] |
| Metabolism. | Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes [Pubmed:25034387] |
| J Am Heart Assoc | Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients [PubMed: 26374297] |
| Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie | V [Ebscohost] |
| Endocrinol Metab (Seoul). | Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2?in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome [pmc:PMC4803547] |
| Clin Pharmacol Ther.? | Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery [Pubmed:25773594] |
| Lipids in Health and Disease | Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly … [articles:10.1186] |
| Acta Endocrinologica | SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA. [jrnl:1841098] |
| Biomarker for diagnosis of moyamoya disease [:] | |
| JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions [Pubmed: 32859455] |
| chinese neurosurgical journal | Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage? [] |
